English
As China’s pharmaceutical and medical device players are starting to show scale, they are bound to consolidate. Recently, the majority of China’s deal activity was related to drug manufacturing assets and drug commercialization, which is different to several years ago when CRO services were the name of the game. Many local players have reshuffled their investment portfolios and acquired other domestic companies, driving the consolidation forward in terms of production capacities as well as sales & distribution channels. On the other hand, foreign pharma players realized that China has become the world’s second largest drug market that keeps growing at 15 – 18% p.a., and they keep trying to find a fast entry or expansion in the Chinese market via M&A. In the medical device sector, larger foreign players have started to acquire the domestic top players (as very evident in orthopedics), not the least to bridge registration issues of their import portfolios. With a domestic market continuing to grow at fast speed, deal valuations will remain higher compared to other industries in the years to come.
Healthcare
Healthcare Introduction
Our latest transactions
CHINA
acquired
Sonova AG advised by
InterChina
InterChina
acquired interest in
Buyer advised by
InterChina
InterChina
acquired 100% of
Buyer advised by
InterChina
InterChina
acquired a controlling stake in
Buyer advised by
InterChina
InterChina
acquired
Buyer advised by
InterChina
InterChina
divested its equity holdings in Anhui MZC to
Medichem advised by
InterChina
InterChina
acquires infusion assets from
BD advised by
InterChina
InterChina
© 2019 InterChina All rights reserved. All landscape photographs are taken in China copyright owned by Mr. Yaonan Long.